Bioatla Investor Relations Material
Latest events
Q1 2025
Bioatla
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Bioatla Inc
Access all reports
Bioatla Inc is a clinical-stage biopharmaceutical company specializing in the development of novel monoclonal antibody and cell-based therapeutics for the treatment of solid tumor cancers. Utilizing its proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms, Bioatla is focused on creating therapies with improved selectivity for the tumor microenvironment, potentially enhancing safety and therapeutic efficacy. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
BCAB
Country
🇺🇸 United States